SecondWave Systems, Inc. has successfully closed a $7M Series A financing round to support the development of its innovative ultrasound-based treatment for inflammatory disorders.

Target Information

SecondWave Systems, Inc. is a clinical-stage medical device company based in St. Paul, Minnesota, focused on developing innovative ultrasound-based treatments for inflammatory disorders. The company has recently announced the successful closure of a $7 million Series A financing round, which will support the execution of their next clinical study. This follows a promising first-in-human study that demonstrated a significant reduction in disease activity for patients suffering from rheumatoid arthritis.

The flagship product, the SecondWave MINI™, is a groundbreaking non-invasive and wearable therapeutic ultrasound device designed specifically for treating inflammatory diseases. By utilizing proprietary low-intensity focused ultrasound technology, the device aims to stimulate the spleen, providing a novel therapeutic option for both acute and chronic inflammation disorders. Clinical studies are currently in progress to evaluate its efficacy across multiple inflammation-related conditions.

Industry Overview in the United States

The healthcare industry in the United States is evolving rapidly, particularly in the realm of medical devices and technologies aimed at treating chronic diseases. With the prevalence of inflammatory disorders on the rise, there is a growing demand for innovative treatment optio